XML 35 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Recently Adopted and Issued Accounting Guidance - Consolidated Balance Sheets (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2018
USD ($)
segment
Dec. 31, 2017
USD ($)
Accounting Changes and Error Corrections [Abstract]    
Number of reportable segments | segment 2  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]    
Other current assets $ 6,954 $ 5,153
Other assets 1,320 891
Total assets   344,454
Accrued expenses and other liabilities 9,884 7,550
Long-term pharma contract liability 522 283
Deferred income tax liability, net 6,594 6,688
Stockholders' Equity 172,545 171,962
Total Liabilities and Stockholders' Equity $ 349,272 344,454
Scenario, Previously Reported    
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]    
Other current assets   4,241
Other assets   689
Total assets   343,340
Accrued expenses and other liabilities   6,144
Long-term pharma contract liability   0
Deferred income tax liability, net   6,307
Stockholders' Equity   172,918
Total Liabilities and Stockholders' Equity   343,340
Restatement Adjustment | Accounting Standards Update 2014-09    
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]    
Other current assets   912
Other assets   202
Total assets   1,114
Accrued expenses and other liabilities   1,406
Long-term pharma contract liability   283
Deferred income tax liability, net   381
Stockholders' Equity   (956)
Total Liabilities and Stockholders' Equity   $ 1,114